Alterity Therapeutics announces ATH434 Phase 2 trial results
Clinical Trial Results: Alterity Therapeutics announced positive topline results from the Phase 2 trial of ATH434, showing significant slowing of clinical progression in early-stage multiple system atrophy (MSA) patients, with a 48% reduction at the 50 mg dose and 29% at the 75 mg dose over 52 weeks compared to placebo.
Future Development Plans: The company plans to engage with the FDA to discuss accelerating the development of ATH434, emphasizing its potential as a disease-modifying treatment for MSA, which currently lacks approved therapies.
Trade with 70% Backtested Accuracy
Analyst Views on ATHE
About ATHE
About the author
Alterity Advances ATH434 in Late-Stage Development for Multiple System Atrophy
- Clinical Trial Progress: Alterity Therapeutics is advancing its candidate drug ATH434 in clinical development for Multiple System Atrophy (MSA), a rapidly progressive neurodegenerative disease with no approved therapies, demonstrating significant clinical benefits and a favorable safety profile.
- Efficacy Data: In the Phase 2 clinical trial of ATH434, 77 participants underwent 12 months of treatment, with results showing significant improvements in functional ratings compared to placebo, indicating its potential to enhance patients' daily living capabilities.
- Biomarker Application: The clinical program incorporates biomarkers and advanced neuroimaging to better assess disease progression and therapeutic impact, thereby supporting the development of disease-modifying therapies and enhancing understanding of this complex condition.
- Patient Advocacy and Awareness: During MSA Awareness Month, Alterity will share educational information via social media, emphasizing support for the MSA community and showcasing the company's commitment to addressing the significant unmet needs in this field.
Alterity Therapeutics Completes Phase 2 Trials for ATH434, Targeting $2.4 Billion Market
- Clinical Trial Success: In 2025, Alterity successfully completed Phase 2 trials for ATH434, demonstrating strong safety and efficacy signals, paving the way for a transition to Phase 3 trials, which is expected to unlock significant market opportunities.
- Significant Market Potential: ATH434 targets Multiple System Atrophy (MSA), a condition currently lacking effective treatments, with a potential market size of $2.4 billion, and successful advancement will greatly enhance Alterity's competitive position in the biotech sector.
- Regulatory Alignment Plans: Alterity plans to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize the design and key clinical endpoints for Phase 3 trials, ensuring compliance and effectiveness in clinical development.
- Strengthened Leadership Team: In 2025, Alterity enhanced its governance structure by appointing Julian Babarczy as the new Chair of the Board, increasing the leadership team's expertise and market responsiveness, preparing for critical milestones in 2026.
Alterity Therapeutics: Q1 FY26 Cash Flow Report - Appendix 4C
Clinical Trial Results: New analysis from the ATH434-201 trial shows strengthened efficacy at a high dose for treating Multiple System Atrophy (MSA), with positive outcomes also reported in the ATH434-202 open-label trial for advanced MSA patients.
Market Potential: An independent assessment indicates a potential peak sales opportunity of USD $2.4 billion for ATH434 in the MSA market, driven by strong physician interest based on Phase 2 trial results.
Regulatory Engagement: Alterity Therapeutics is actively engaging with the U.S. FDA to discuss necessary data for advancing ATH434 into Phase 3 trials, following a series of Type C meetings to align on clinical development topics.
Financial Position: As of September 30, 2025, Alterity reported a cash balance of A$54.56 million, with operating cash outflows of A$5.34 million for the quarter, and successfully raised A$20 million from a strategic placement to support its programs.
Alterity Therapeutics Showcases Encouraging Results from ATH434 Phase 2 Trial at the 2025 International Congress on Parkinson's Disease and Movement Disorders
ATH434 Clinical Trial Results: Data from the Phase 2 trial of ATH434 in Multiple System Atrophy (MSA) show it slows disease progression and stabilizes orthostatic hypotension, with significant improvements observed in clinical endpoints compared to placebo.
Neuroimaging and Biomarker Analysis: Advanced neuroimaging and biomarker assessments in the trial enhance the understanding of MSA diagnosis and track disease evolution, indicating a multimodal approach may improve diagnostic accuracy.
Alterity Therapeutics to Present Several Talks at the 2025 International Congress on Parkinson's Disease and Movement Disorders
Clinical Trial Presentation: Data from Alterity Therapeutics' ATH434-201 Phase 2 trial in Multiple System Atrophy (MSA) will be presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders, highlighting its potential as a first-ever treatment for MSA.
Efficacy and Safety Results: The trial demonstrated significant clinical efficacy, improved motor performance, and a favorable safety profile for ATH434, which is designed to inhibit protein aggregation associated with neurodegeneration.
Alterity Therapeutics Set to Showcase at the Biotech Conference
Corporate Update Announcement: Alterity Therapeutics will present a corporate update at the Biotech Showcase on September 3, 2025, in Australia and September 2, 2025, in the U.S., focusing on their advancements in neurodegenerative disease treatments.
Clinical Trial Progress: The company has shown promising results for its lead asset, ATH434, in clinical trials for Multiple System Atrophy (MSA), a rare Parkinsonian disorder, and is actively developing therapies for Parkinson's disease and related conditions.
Alterity Advances ATH434 in Late-Stage Development for Multiple System Atrophy
- Clinical Trial Progress: Alterity Therapeutics is advancing its candidate drug ATH434 in clinical development for Multiple System Atrophy (MSA), a rapidly progressive neurodegenerative disease with no approved therapies, demonstrating significant clinical benefits and a favorable safety profile.
- Efficacy Data: In the Phase 2 clinical trial of ATH434, 77 participants underwent 12 months of treatment, with results showing significant improvements in functional ratings compared to placebo, indicating its potential to enhance patients' daily living capabilities.
- Biomarker Application: The clinical program incorporates biomarkers and advanced neuroimaging to better assess disease progression and therapeutic impact, thereby supporting the development of disease-modifying therapies and enhancing understanding of this complex condition.
- Patient Advocacy and Awareness: During MSA Awareness Month, Alterity will share educational information via social media, emphasizing support for the MSA community and showcasing the company's commitment to addressing the significant unmet needs in this field.
Alterity Therapeutics Completes Phase 2 Trials for ATH434, Targeting $2.4 Billion Market
- Clinical Trial Success: In 2025, Alterity successfully completed Phase 2 trials for ATH434, demonstrating strong safety and efficacy signals, paving the way for a transition to Phase 3 trials, which is expected to unlock significant market opportunities.
- Significant Market Potential: ATH434 targets Multiple System Atrophy (MSA), a condition currently lacking effective treatments, with a potential market size of $2.4 billion, and successful advancement will greatly enhance Alterity's competitive position in the biotech sector.
- Regulatory Alignment Plans: Alterity plans to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize the design and key clinical endpoints for Phase 3 trials, ensuring compliance and effectiveness in clinical development.
- Strengthened Leadership Team: In 2025, Alterity enhanced its governance structure by appointing Julian Babarczy as the new Chair of the Board, increasing the leadership team's expertise and market responsiveness, preparing for critical milestones in 2026.
Alterity Therapeutics: Q1 FY26 Cash Flow Report - Appendix 4C
Clinical Trial Results: New analysis from the ATH434-201 trial shows strengthened efficacy at a high dose for treating Multiple System Atrophy (MSA), with positive outcomes also reported in the ATH434-202 open-label trial for advanced MSA patients.
Market Potential: An independent assessment indicates a potential peak sales opportunity of USD $2.4 billion for ATH434 in the MSA market, driven by strong physician interest based on Phase 2 trial results.
Regulatory Engagement: Alterity Therapeutics is actively engaging with the U.S. FDA to discuss necessary data for advancing ATH434 into Phase 3 trials, following a series of Type C meetings to align on clinical development topics.
Financial Position: As of September 30, 2025, Alterity reported a cash balance of A$54.56 million, with operating cash outflows of A$5.34 million for the quarter, and successfully raised A$20 million from a strategic placement to support its programs.
Alterity Therapeutics Showcases Encouraging Results from ATH434 Phase 2 Trial at the 2025 International Congress on Parkinson's Disease and Movement Disorders
ATH434 Clinical Trial Results: Data from the Phase 2 trial of ATH434 in Multiple System Atrophy (MSA) show it slows disease progression and stabilizes orthostatic hypotension, with significant improvements observed in clinical endpoints compared to placebo.
Neuroimaging and Biomarker Analysis: Advanced neuroimaging and biomarker assessments in the trial enhance the understanding of MSA diagnosis and track disease evolution, indicating a multimodal approach may improve diagnostic accuracy.
Alterity Therapeutics to Present Several Talks at the 2025 International Congress on Parkinson's Disease and Movement Disorders
Clinical Trial Presentation: Data from Alterity Therapeutics' ATH434-201 Phase 2 trial in Multiple System Atrophy (MSA) will be presented at the 2025 International Congress of Parkinson's Disease and Movement Disorders, highlighting its potential as a first-ever treatment for MSA.
Efficacy and Safety Results: The trial demonstrated significant clinical efficacy, improved motor performance, and a favorable safety profile for ATH434, which is designed to inhibit protein aggregation associated with neurodegeneration.
Alterity Therapeutics Set to Showcase at the Biotech Conference
Corporate Update Announcement: Alterity Therapeutics will present a corporate update at the Biotech Showcase on September 3, 2025, in Australia and September 2, 2025, in the U.S., focusing on their advancements in neurodegenerative disease treatments.
Clinical Trial Progress: The company has shown promising results for its lead asset, ATH434, in clinical trials for Multiple System Atrophy (MSA), a rare Parkinsonian disorder, and is actively developing therapies for Parkinson's disease and related conditions.
